Trial · NCT04842292
Nebulized Heparin for COVID19-associated Acute Respiratory Failure
NCT04842292, Phase 2, Terminated, Brittany Bissell; results first posted 2022-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nebulized Heparin for COVID19-associated Acute Respiratory Failure. Trials, record NCT04842292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04842292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nebulized Heparin for COVID19-associated Acute Respiratory Failure
- NCT number
- NCT04842292
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Brittany Bissell
- Conditions
- Covid19
- Interventions
- Heparin, Placebo
- First posted
- 2021-04-13
- Last updated
- 2022-10-18
- Results first posted
- 2022-10-18
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean PaO2/FiO2 Ratio | Within the first 10 days of ICU stay or up until ICU discharge, whichever occurs first | |
| Secondary | Clinically Significant Bleeding | Up to discharge or 3 months following enrollment, whichever occurs first | |
| Secondary | Incidence of Venous Thromboembolism | Up to discharge or 3 months following enrollment, whichever occurs first |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean PaO2/FiO2 Ratio | Within the first 10 days of ICU stay or up until ICU discharge, whichever occurs first | Two participants were enrolled in this study. Due to the possibility that participants could reasonably be identified due to low enrollment, data cannot be presented. | units on a scale | MEAN |
| SECONDARY | Clinically Significant Bleeding | Up to discharge or 3 months following enrollment, whichever occurs first | Two participants were enrolled in this study. Due to the possibility that participants could reasonably be identified due to low enrollment, data cannot be presented. | units on a scale | MEAN |
| SECONDARY | Incidence of Venous Thromboembolism | Up to discharge or 3 months following enrollment, whichever occurs first | Two participants were enrolled in this study. Due to the possibility that participants could reasonably be identified due to low enrollment, data cannot be presented. | Incidence | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean PaO2/FiO2 Ratio | Participants | NA | Standard Deviation NA | units on a scale | |
| Clinically Significant Bleeding | Participants | NA | Standard Deviation NA | units on a scale | |
| Incidence of Venous Thromboembolism | Participants | NA | Incidence |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants | 2 | |
| Overall Study | COMPLETED | Participants | 2 | |
| Overall Study | NOT COMPLETED | Participants | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants | 1 | 2 |
| Total, other adverse events | Participants | 0 | 2 |
| Total, serious adverse events | Participants | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04842292
GET https://conductscience.org/api/trials/v1/NCT04842292/registered